IPAX-Linz Study Reports Promising Efficacy for TLX101 Glioma Therapy Candidate
![]() |
MELBOURNE, Australia and INDIANAPOLIS, April 16, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces preliminary results from the Phase 2 IPAX-Linz study of TLX101 (131I-iodofalan[1]) in recurrent high-grade glioma (brain cancer), substantiating the patient benefit seen in the IPAX-1...
Read more: IPAX-Linz Study Reports Promising Efficacy for TLX101 Glioma Therapy Candidate